Diagnosis
One in three Europeans unfamiliar with cystitis and UTIs, survey finds

One in three Europeans cannot identify cystitis as a bladder infection, with some mistaking it for conditions such as skin problems or food allergies.
A survey of more than 3,000 adults in France, Germany, Italy, Spain and the UK found 35 per cent could not define the condition.
Awareness was lowest among 18–24 year olds, with only 45 per cent answering correctly.
Prof Gernot Bonkat, chair of the EAU Infections Guidelines Panel, said the consequences are global.
Bonkat said: “Urinary tract infections affect over 400 million people worldwide and cause approximately 240,000 deaths each year, with rising antibiotic resistance making them harder to treat.
“This study shows that raising public awareness, as well as education about symptoms, causes and treatment, is still essential to prevent infections, reduce suffering and slow the spread of resistance. Not every infection needs to be treated with antibiotics — careful use is key to combating resistance.”
The European Association of Urology carried out the research for Urology Week 2025 (22–26 September), which this year focuses on UTIs and cystitis.
Although women are far more likely to develop UTIs, just 51 per cent of respondents recognised this. Almost one in five men wrongly believed men are more commonly affected. Women showed greater awareness, with 63 per cent identifying their higher risk compared with 38 per cent of men.
Knowledge of prevention was limited. While 71 per cent knew that drinking plenty of water helps, only 43 per cent mentioned hygiene measures such as wiping front to back. Just 35 per cent identified urinating after sex as a key prevention method. Seventeen per cent mistakenly thought taking antibiotics without medical advice could prevent UTIs.
Only 21 per cent of respondents identified all three main prevention strategies, while one in six could not name a single one. Women were three times more likely than men to identify all three.
Jane Meijlink, chair of the International Painful Bladder Foundation, said young women were of particular concern.
She said: “Many teenagers today are sexually active without understanding the risks of bladder infections.
“Young women in particular are more vulnerable because of their anatomy, yet too often they think the contraceptive pill protects them from all risks and that condoms are unnecessary.
“We urgently need to address this through school education and social media, otherwise we risk a new generation of young women suffering repeated urinary tract infections and even long-term bladder damage.”
Misunderstandings about antibiotics added to the problem.
While not every UTI requires treatment, 16 per cent believed antibiotics are always needed. Nearly half underestimated or were unaware of the growing difficulty of treatment due to resistance.
Prof Gernot Bonkat, chair of the EAU Infections Guidelines Panel, said the consequences are global.
Bonkat said: “Urinary tract infections affect over 400 million people worldwide and cause approximately 240,000 deaths each year, with rising antibiotic resistance making them harder to treat.
“This study shows that raising public awareness, as well as education about symptoms, causes and treatment, is still essential to prevent infections, reduce suffering and slow the spread of resistance. Not every infection needs to be treated with antibiotics — careful use is key to combating resistance.”
UTIs are the second most common infection after respiratory illnesses.
Around 50 to 60 per cent of women will experience at least one during their lifetime.
They are a major public health concern, with global costs estimated in the billions of euros annually.
Pregnancy
Home blood pressure checks could lower heart risks for new mothers – study
Diagnosis
Researchers teach AI to spot cancer risk by squeezing individual breast cells
Diagnosis
Experimental drug drowns triple-negative breast cancer cells in toxic fats

An experimental drug slowed triple-negative breast cancer in mice by flooding tumour cells with toxic fats.
Triple-negative breast cancer lacks three common drug targets, making it one of the hardest-to-treat and most aggressive forms of the disease.
The compound, known as DH20931, appears to push cancer cells past their limits by triggering a surge in ceramides, fat-like molecules that place the cells under intense stress until they self-destruct.
In lab experiments, the drug also made standard chemotherapy more effective. When combined with doxorubicin, researchers were able to reduce the dose needed to kill cancer cells by about fivefold.
The drug targets an enzyme known as CerS2 to sharply increase production of these lipids and stress cancer cells. Healthy cells, by contrast, showed lower sensitivity to the drug in lab tests.
While the early results are promising, further preclinical and clinical trials would still be needed to determine the safety and effectiveness of DH20931 in humans.
Satya Narayan, a professor in the University of Florida’s College of Medicine, led the study with an international group of collaborators.
The researchers published their results on human-derived tumours on 21 April and presented their findings on combination therapy at the annual meeting of the American Association for Cancer Research in San Diego.
Narayan likened the drug’s effects to a home’s electrical system handling a power surge.
While healthy cells act like a properly grounded and installed circuit, cancer cells are more like a jumble of mismatched wires and faulty fuses. DH20931 overwhelms cells not with electricity, but with fats.
He said: “When that surge goes into the cancer cells, they cannot handle the amount of power they are getting. The fuses burn out, the cell can’t handle the surge and it dies.”
The compound was developed at the University of Florida in the lab of Sukwong Hong.
Hong, now a professor at the Gwangju Institute of Science and Technology in South Korea, created DH20931 as one of many drug candidates tested for efficacy in Narayan’s lab.
In the study, researchers implanted human triple-negative breast cancer tumours into mice and treated them with DH20931.
The drug significantly slowed tumour growth without causing noticeable weight loss or signs of toxicity in the animals. In separate lab experiments, it also showed activity against other breast cancer subtypes.
In addition to increasing lipid levels, DH20931 triggers a second stress signal by flooding cells with calcium.
Together, these effects disrupt the mitochondria, the structures that produce a cell’s energy, ultimately leading to cell death.
Narayan said: “It does not just follow one pathway but it goes through multiple pathways. It’s a two-hit hypothesis.
“These pathways are common in all breast cancer types and other solid tumours, so we think this drug can be useful not only in triple-negative breast cancer but potentially other cancers as well.”
Entrepreneur4 weeks agoThree sessions that show exactly where women’s health is heading in 2026
Entrepreneur4 days agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
Pregnancy4 weeks agoHow NIPT has evolved and what AI NIPT means in 2026
News4 weeks agoTwo weeks left to make your mark in women’s cardiovascular health
Opinion4 weeks agoQ1 momentum: Female founders are advancing, but the system still hasn’t caught up
Fertility2 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Mental health6 days agoLifting weights shows mental health and cognitive benefits in older women, study finds
Menopause2 weeks agoMore research needed to understand link between brain fog and menopause, expert says














